Arista™AH is indicated in surgical procedures as an adjunctive hemostatic device in the control of capillary, venous and arteriolar bleeding.

Arista™AH is a sterile, absorbable hemostatic powder consisting of Microporous Polysaccharide Hemospheres (MPH®), Medafor's patented clotting technology derived from purified plant starch.

When applied directly to the source of bleeding, Arista™AH begins clotting on contact, achieving complete hemostasis, in most cases, within minutes.

Position the Arista™AH applicator and apply powder to the bleeding site.

Unlike other surgical hemostats which claim to be "ready when you are" but which can require minutes to hours for preparation, Arista™AH requires:

  • NO mixing
  • NO additional components
  • NO assembly
  • NO special storage conditions

Arista™AH begins clotting on contact and achieves complete hemostasis in a matter of minutes. The flowable particles provide complete coverage on both rough surfaces and in small, hard-to-reach spaces.

Arista™AH is a natural composition synthesized from a purified plant polymer and free of all biological components. As such, it is non toxic, non irritating, non hemolytic and non mutagenic. Arista™AH reaches its maximum volume immediately upon contact with blood or other fluids. In clinical studies, Arista™AH has produced no adverse reactions. It is non immunogenic, fully biocompatible and readily absorbed in tissue in 24 to 48 hours.

Unlike other surgical hemostats, Arista™AH:

  • is fully and safely ABSORBABLE – within 24 to 48 hours (min. absorption time for other surgical hemostats is typically 3-8 weeks)
  • contains NO HUMAN OR ANIMAL components
  • DOES NOT SERVE AS A NIDUS FOR INFECTION OR GRANULOMA FORMATION
  • is ready INSTANTLY, requiring NO PREPARATION TIME
  • is CELL SAVER COMPATIBLE

Arista™AH is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical.

See Administration section of Instructions for Use (PDF) document.

Medafor, Inc., was founded in 1999 to develop and market applications for its patented MPH® (Microporous Polysaccharide Hemospheres Technology). Statements presented on this page have not been evaluated by the U.S. FDA. See respective Instructions for Use for product applications and indications. Site content and images Copyright 2008 Medafor, Inc. All Rights Reserved. No part of this site may be copied, republished, excerpted or transferred to other media without the express written consent of Medafor, Inc. Arista™AH, MPH®, Medafor®, MPatcH®, FlexiTip™ are trademarks of Medafor, Inc. Other trademarks mentioned are the property of their respective companies. For information, contact Medafor at 1-763-571-6300.